化疗止吐新药阿瑞匹坦成功在华上市

Nausea and vomiting are common adverse reactions of chemotherapy, which can affect patients' chemotherapy compliance and quality of life. Therefore, effectively controlling nausea and vomiting caused by chemotherapy is of great significance for the treatment of clinical malignant tumors. Aprepitant has high affinity and selectivity for the receptor NK1 and can block substance P by binding to the NK1 receptor, but its affinity for receptors such as 5-hydroxytryptamine 3 and dexamethasone is relatively low. Therefore, Aprepitant combined with other receptor antagonists can improve nausea and vomiting caused by chemotherapy. The latest 2014 "Guidelines for the Prevention and Treatment of Vomiting Related to Tumor Treatment" recommends the "triple regimen" - 5-HTr8 receptor antagonist, combined with dexamethasone, as the current first-line anti-emetic treatment plan for chemotherapy. It starts from the "dual pathways" of the central nervous system and the gastrointestinal tract to comprehensively solve the nausea and vomiting problems caused by chemotherapy and allow patients to treat with peace of mind. Nowadays, the new chemotherapy anti-emetic drug aprepitant has been successfully launched in China.

A foreign phase III clinical trial of Aprepitant showed that patients treated with high-dose cisplatin were randomly divided into the aprepitant group (aprepitant combined with ondansetron and dexamethasone on day 1, aprepitant and dexamethasone on days 2 to 3, and dexamethasone on day 4) and standard treatment. In the quasi-antiemetic regimen group (ondansetron and dexamethasone on day 1, and dexamethasone on days 2 to 4), the CR rates for acute vomiting were 89.2% and 78.1% (P<0.001), respectively, and the CR rates for delayed vomiting were 75.4% and 55.8% (P<0.001) respectively. The triple antiemetic regimen with the addition of aprepitant is more effective than the double regimen in treating acute and delayed vomiting.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.